RLVT 09-03
Alternative Names: RLVT-09-03Latest Information Update: 02 Dec 2022
At a glance
- Originator Releviate Therapeutics
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action Matrix metalloproteinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 18 Oct 2022 Phase-I clinical trials in Neuropathic pain in USA (IV) Releviate Therapeutics pipeline, October 2022
- 18 Oct 2022 Preclinical trials in Neuropathic pain in USA (IV) (Releviate Therapeutics pipeline, October 2022)
- 18 Oct 2022 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by Releviate Therapeutics (Releviate Therapeutics pipeline, October 2022)